IGF-1 LR3: Mechanisms, Benefits, Dosing, and Safety Profile

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

IGF-1 LR3 is a long-acting analogue of Insulin-like Growth Factor 1 with a half-life of 20–30 hours. It promotes muscle hyperplasia (new muscle cells), fat oxidation, and recovery. Typical dose: 20–50 mcg post-workout. Requires careful glucose monitoring due to hypoglycemia risk.

What Is IGF-1 LR3?

Insulin-like Growth Factor 1 Long R3 (IGF-1 LR3) is a synthetic analogue of human IGF-1, modified to have significantly reduced binding to IGF-binding proteins (IGFBPs). This modification extends its half-life from approximately 12–15 hours to 20–30 hours, allowing for less frequent dosing and more sustained anabolic activity.

Mechanisms of Action

IGF-1 LR3 exerts its effects through binding to the IGF-1 receptor (IGF-1R), activating the PI3K/Akt/mTOR pathway (the primary driver of muscle protein synthesis), the MAPK/ERK pathway (promoting cell proliferation), inhibition of apoptosis, and stimulation of glucose uptake in muscle tissue. Critically, IGF-1 promotes muscle hyperplasia — the creation of new muscle cells — in addition to hypertrophy.

Benefits

Research and clinical experience suggest IGF-1 LR3 offers: accelerated muscle growth (both hypertrophy and hyperplasia), enhanced fat oxidation, improved recovery from training and injury, increased nutrient partitioning, and potential neuroprotective effects.

Dosing Protocol

Typical research protocols use 20–50 mcg of IGF-1 LR3 administered subcutaneously or intramuscularly, once daily post-workout. Cycles typically run 4–6 weeks, followed by an equal off period to prevent receptor desensitization.

Safety Considerations

The most significant acute risk with IGF-1 LR3 is hypoglycemia. Because IGF-1 shares structural homology with insulin, it can lower blood glucose, particularly when combined with post-workout carbohydrate depletion. Always have fast-acting carbohydrates available. Long-term concerns include the theoretical risk of promoting growth in pre-existing cancer cells. Individuals with a personal or family history of cancer should avoid IGF-1 LR3.

Conclusion

IGF-1 LR3 is a potent anabolic peptide with a unique mechanism of action — promoting muscle hyperplasia in addition to hypertrophy. Its extended half-life makes it more practical than native IGF-1 for research purposes. However, its risk profile means it should be approached with caution and thorough understanding of its pharmacology.